Drugs / ET-02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04933825 | Jul 2021 → Sep 2024 | B-cell neoplasm | EdiGene (GuangZhou) Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ET-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04933825 ↗ |
| Route | Other | “ET-02 injection” NCT04933825 ↗ |